Nucleic acids and corresponding proteins entitled 58P1D12 useful in treatment and detection of cancer
A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.
1. A method for detecting expression levels of a 58P1D12 protein consisting of the sequence of SEQ ID NO: 13 or SEQ ID NO: 14 in a biological sample and normal sample, comprising:
determining expression levels of the 58P1D12 protein in the biological sample and the normal sample; and
comparing the expression levels of the 58P1D12 protein detected in the biological sample and the normal sample.
2. The method of claim 1 , wherein the biological sample is from a patient who has or is suspected of having a cancer selected from the group consisting of prostate cancer, bladder cancer, lung cancer, ovarian cancer, bone cancer, and cervical cancer.
3. The method of claim 1 , wherein the biological sample is from serum, blood or urine, or tissue selected from the group consisting of prostate, bladder, lung, ovary, bone, and cervix.
4. The method of claim 1 , wherein the presence of elevated 58P1D12 protein in the biological sample relative to the normal sample provides an indication of the presence of cancer.
5. The method of claim 1 , wherein the 58P1D12 protein consists of the sequence of SEQ ID NO: 13.
6. The method of claim 1 , wherein the 58P1D12 protein consists of the sequence of SEQ ID NO: 14.
7. A method for detecting expression levels of a 58P1D12 transcription variant polynucleotide encoding a protein consisting of the sequence of SEQ ID NO: 13 or SEQ ID NO: 14 in a biological sample and a corresponding normal sample, comprising:
determining expression levels of the 58P1D12 transcription variant polynucleotide in the biological sample and the corresponding normal sample; and
comparing the expression levels of the 58P1D12 transcription variant polynucleotide detected in the biological sample and the corresponding normal sample, wherein the biological sample is from a patient who has or is suspected of having a cancer selected from the group consisting of prostate cancer, bladder cancer, lung cancer, ovarian cancer, bone cancer, and cervical cancer.
8. The method of claim 7 , wherein the biological sample is from serum, blood or urine, or tissue selected from the group consisting of prostate, bladder, lung, ovary, bone, and cervix.
9. The method of claim 7 , wherein the presence of elevated 58P1D12 transcription variant polynucleotide in the biological sample relative to the corresponding normal sample provides an indication of the presence of cancer.
10. The method of claim 7 , wherein the 58P1D12 transcription variant polynucleotide comprises the sequence of SEQ ID NO: 4.
11. The method of claim 7 , wherein the 58P1D12 transcription variant polynucleotide comprises the sequence of SEQ ID NO: 8.